SQZ Biotech completes oversubscribed $72M Series C SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing. New investors include Everblue, Illumina Ventures, Invus, Orient … Continued
Lilly Completes Acquisition of ARMO BioSciences Eli Lilly and Company(NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO). Lilly’s tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 per share … Continued
Founders Fund Leads $36 Million Financing Round in Emulate Emulate, Inc. today announced that it has secured a $36 million Series C financing round led by Founders Fund. The funding also includes additional new investors including ALS Investment Fund, SciFi VC, … Continued
Lilly Announces Agreement To Acquire ARMO BioSciences for $1.6B in an all-cash transaction Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash … Continued
Organ-Chips Accurately Model and Predict Thrombotic Side Effect Caused by Anti-CD154 Monoclonal Antibody hu5c8; Emulate Publishes Results of Collaborative Research with Janssen Emulate, Inc. announced today a published study that demonstrates that its Blood Vessel-Chip accurately modeled and predicted thrombosis, … Continued
Crocus Technology Raises $35M in Financing Crocus Technology, a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces it has secured $35M in funding through a combination of debt and equity from internal investors and external sources. The funding … Continued
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a long-acting PEGylated form of recombinant human … Continued
Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that it has dosed the first patient in a Phase 1/2a study evaluating PEN-866 in patients … Continued
Twist Bioscience Accelerates Global Expansion with Strategic Asia Pacific Distribution Agreements Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that the company has expanded its presence in Asia Pacific, adding … Continued
Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress 3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained … Continued